Washington Post Publisher Will Lewis Steps Down After Layoffs 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
BURLINGAME, Calif., April 05, 2016 -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced oral and poster presentations of key preclinical data relating to certain of its drug development programs at the American Association of Cancer Research (AACR) Annual Meeting, April 16-20, 2016 in New Orleans.
Following are the specifics for Corvus’ two poster presentations:
- Inhibition of Adenosine A2A Receptor (A2AR) by CPI-444 Enhances CD8+ T cell Killing of a HER-2/neu Expressing Murine Tumor
| Authored by Blake A. Scott1, Todd Armstrong2, Elizabeth M. Jaffee2 |
| Affiliations: 1Johns Hopkins University School of Medicine, Baltimore, MD; 2Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine, Baltimore |
| Session Category: Experimental and Molecular Therapeutics |
| Session Date/ Time: Sunday, Apr 17, 1:00 PM – 5:00 PM |
| Location: Morial Convention Center, Halls G-J, Poster Section 17, Poster Board 1 |
- The Adenosine A2A Receptor Antagonist, CPI-444, Blocks Adenosine-Mediated T Cell Suppression and Exhibits Anti-Tumor Activity Alone and In Combination with Anti-PD-1 and Anti-PD-L1
| Authored by Stephen Willingham1, Po Y. Ho1, Robert Leone2, Emily Piccione1, Carmen Choy1, Andrew Hotson1, Joseph Buggy1, Jonathan Powell2, Richard Miller1 |
| Affiliations: 1Corvus Pharmaceuticals, Burlingame, Calif.; 2Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore |
| Session Category: Immunology |
| Session Date/ Time: Monday, Apr 18, 1:00 PM – 5:00 PM |
| Location: Morial Convention Center, Halls G-J, Poster Section 26, Poster Board 21 |
The following oral presentation will take place as follows:
- Adenosine A2a Receptor (A2aR) Antagonist as a Means of Enhancing the Efficacy of Checkpoint Blockade and Adoptive T Cell Therapy
| Authored by Robert D. Leone, Judson M. Englert, Chih-Hsien Cheng, Jiayu Wen, Min-Hee Oh, Im-Hong Sun, Chirag Patel, Ian A. Bettencourt, Jonathan D. Powell |
| Affiliation: Sidney Kimmel Comprehensive Cancer Research Center Johns Hopkins University School of Medicine, Baltimore |
| Session Category: Immunology |
| Session Date/ Time: Tuesday, Apr 19, 4:20 PM – 4:35 PM |
| Location: Morial Convention Center, New Orleans Theater C |
To learn more about the Corvus pipeline visit http://www.corvuspharma.com/technology/.
ABOUT CORVUS PHARMACEUTICALS
Corvus Pharmaceuticals (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT: Leiv Lea Chief Financial Officer [email protected] 650-900-4522 MEDIA CONTACT: Julie Normart, W2O Group 415-946-1087 [email protected]
